Summit Health CEO Jeff Alter discusses how the acquisition by Walgreens’ VillageMD will affect the company’s growth trajectory.
Mental health patients are staying in hospital emergency departments longer, prompting providers to lobby for regulatory and legislative fixes.
Alzheimer’s drug targets people with mild cognitive impairment. What does that mean?
The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging.